Effectiveness of tofacitinib versus Betamethasone in alopecia areata.
Not Applicable
Completed
- Conditions
- Health Condition 1: L639- Alopecia areata, unspecified
- Registration Number
- CTRI/2022/12/048004
- Lead Sponsor
- All India Institute of Medical Sciences, Jodhpur
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 94
Inclusion Criteria
1. Clinically diagnosed patient of alopecia areata with more than 20% scalp hair loss or rapidly
progressive disease.
2. Age >14 years and <50 years
Exclusion Criteria
1. Previously treated patients within 2 weeks of topical therapy or 4 weeks of systemic therapy
2. Patients who have hepatic impairment
3. Patients with abnormal blood counts (lymphocyte <500cell/mm3 or neutrophils <1000
cell/mm3)
4. Pregnant and lactating women.
5. Immunocompromised patients or if is a K/C/O Hepatitis B,C,or HIV
6. Patient having an active infection, any systemic illness, uncontrolled diabetes mellitus or
hypertension.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in SALT Score.Timepoint: At 4 weeks, 8 weeks, 12 weeks and 16 weeks.
- Secondary Outcome Measures
Name Time Method 1. Physician global assessment score <br/ ><br>2. Patient global assessment score <br/ ><br>3. Dermatology Life Quality Index <br/ ><br>4. Side effectsTimepoint: At 4 weeks, 8 weeks, 12 weeks and 16 weeks.